Geode Capital Management’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
VCM
ACG
EAM
JMFC
Geode Capital Management's DNA Position: Q1 2026 in Review
Geode Capital Management increased its Ginkgo Bioworks (DNA) stake by 0.98% in Q1 2026, buying an estimated $81.2K and bringing the position to 1,009,362 shares worth $6.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2637.
Geode Capital Management first reported a position in DNA in Q4 2021 and has held it in 18 quarters since. The position peaked at $81.1M in Q4 2021. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.
- Geode Capital Management held 1,009,362 shares of Ginkgo Bioworks worth $6.19M as of Q1 2026.
- Geode Capital Management bought 9,762 Ginkgo Bioworks shares in Q1 2026, an estimated $81.2K.
- Ginkgo Bioworks made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2637 holding.
- Geode Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 18 quarters since.
- Geode Capital Management's Ginkgo Bioworks position peaked at $81.1M in Q4 2021.
- 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.